With RediCare Control, patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in weight, HbA1c, blood pressure and improved lipid profiles and PCOS remission. Many type 2 diabetic patients have reduced, and some eliminated their diabetes medications. One study on type 2 diabetic patients saw a 48% normalisation of HbA1c.
RediCare Control is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like type 2 diabetes and heart disease by targeting the causes, not just the effects, using prescription digital therapeutics to deliver personalized lifestyle therapy.
Below is a summary RediCare studies from primary care and corporate setting.
Homewell Practice Study, Havant, UK (Primary Care)
The Homewell Practice Study demonstrated that RediCare Control delivered in a primary care setting in conjunction with a multi-disciplined team was highly effective in treating multi-morbid, insulin dependent patients in a socially deprived setting. Patients with very elevated baseline HbA1c and or morbid obesity respond well to the RediCare Control Digital Therapeutic.
View Study
Marino Medical Study, Bantry, Ireland (Primary Care)
The Marino Medical Centre, Bantry, Co Cork study showed how RediCare Control in an Irish Primary Care setting is effective in treating Type 2 Diabetic, Pre-Diabetic, Hypertensive, Overweight and Obese patients.
View StudyType 2 Diabetes Study, Ireland
This Type 2 Diabetes Study demonstrated that Type 2 Diabetes can be treated effectively and at scale using a digital therapeutic. The study showed 48% of patients normalised their HbA1c while also achieving clinically significant reductions in weight, blood pressure and triglycerides. This study was presented at the EuroPrevent Lisbon 2019.
View StudyMetabolic Syndrome Study, Ireland (Corporate)
This Metabolic Syndrome Study demonstrated that metabolic syndrome can be treated in night shift workers in a corporate setting. Significant reductions in HbA1c and weight were observed.
View StudyWeight Loss Study, Ireland (Multi Corporate)
Prospective study of 232 employee showing clinically significant weight loss and blood pressure reduction from multiple locations form Irish corporate setting. The study was presented at the European Congress of Internal Medicine.
View Study